Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Bachy

Showing results (131-140 of 176) with videos related to

Pageof 18
Sort By:
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Nature Medicine|October 9, 2023
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
American Journal of Hematology|July 29, 2016
Early event status informs subsequent outcome in newly diagnosed follicular lymphomaMatthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, et al.
Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2023
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA StudyGuillaume Cartron, Emmanuel Bachy, Hervé Tilly, et al.
Haematologica|June 20, 2024
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registryCharles Herbaux, Caroline Bret, Emmanuel Bachy, et al.
Cancer Cell|July 31, 2018
Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/LymphomaMasao Nakagawa, Arthur L Shaffer, Michele Ceribelli, et al.
Haematologica|March 9, 2023
Post-transplantation Burkitt lymphoma: a retrospective study of 55 patientsPierre Walczak, Sylvain Choquet, Jacques Dantal, et al.
The Lancet. Haematology|May 25, 2024
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 studyJehan Dupuis, Emmanuel Bachy, Franck Morschhauser, et al.
Pageof 18

Showing results (131-140 of 176) with videos related to

Sort By:
Pageof 18
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Nature Medicine|October 9, 2023
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
American Journal of Hematology|July 29, 2016
Early event status informs subsequent outcome in newly diagnosed follicular lymphomaMatthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, et al.
Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2023
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA StudyGuillaume Cartron, Emmanuel Bachy, Hervé Tilly, et al.
Haematologica|June 20, 2024
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registryCharles Herbaux, Caroline Bret, Emmanuel Bachy, et al.
Cancer Cell|July 31, 2018
Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/LymphomaMasao Nakagawa, Arthur L Shaffer, Michele Ceribelli, et al.
Haematologica|March 9, 2023
Post-transplantation Burkitt lymphoma: a retrospective study of 55 patientsPierre Walczak, Sylvain Choquet, Jacques Dantal, et al.
The Lancet. Haematology|May 25, 2024
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 studyJehan Dupuis, Emmanuel Bachy, Franck Morschhauser, et al.
Pageof 18